Assertio Scoops Up Spectrum Pharma In $248M Stock Deal
- Assertio Holdings Inc will acquire Spectrum Pharmaceuticals Inc in an all-stock and contingent value rights (CVR) transaction.
- Under the terms of the agreement, each Spectrum share will be exchanged for a fixed exchange ratio of 0.1783 shares of Assertio common, implying an upfront value of $1.14 per Spectrum share.
- Additionally, Spectrum stockholders will receive one CVR per Spectrum share, entitling them to receive up to an additional $0.20 per share (approximately $43 million), payable in cash or stock at Assertio's election, for $1.34 (approximately $291 million), by the end of 2024 and 2025..
- Following the close of the transaction, Assertio stockholders will own approximately 65% of the combined company, and Spectrum stockholders will own approximately 35% on a fully diluted basis.
- "The addition of Spectrum's commercial capabilities and Rolvedon, a novel long-acting G-CSF product recently launched into a blockbuster market in October 2022, exemplifies Assertio's attractiveness as an acquirer of new, accretive assets across diverse therapeutic categories," Assertio's president and CEO Dan Peisert said.
- The transaction is expected to be accretive to Assertio's adjusted EPS and operating cash flow in 2024.
- Assertio intends to add operating costs of approximately $60 million annually.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.